CHI3L1 and glioblastoma: Faibish, et al. found that YKL-40 up-regulates VEGF production in the glioblastoma cell line, U87, and demonstrated that monoclonal antibodies targeting YKL-40 activity are a promising strategy for treating advanced tumors [13].